Santhera Pharmaceuticals Holding AG
No trades
No trades
Peers for comparison
−2.280 CHF
−49.24 M CHF
77.19 M CHF
12.16 M
Next report date
Report period
EPS estimate
Revenue estimate
Company info
Sector
Industry
CEO
Orlando Oliveira
Website
Headquarters
Pratteln
Founded
1998
IPO date
Nov 3, 2006
ISIN
CH1276028821
FIGI
BBG006M6ZJR9
Identifiers
ISIN CH1276028821
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, S3F0 trades at 14.965 CHF.
For broader market analysis, dive into the technicals on the Santhera Pharmaceuticals Holding AG stock price chart and read the latest S3F0 news:
– Santhera Pharmaceuticals Holding AG (SANN) Signs AGAMREE Deal Covering 31 Countries
– Santhera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the Caribbean
– Santhera Pharmaceuticals (SANN) Partner Files AGAMREE MAA in South Korea
For broader market analysis, dive into the technicals on the Santhera Pharmaceuticals Holding AG stock price chart and read the latest S3F0 news:
– Santhera Pharmaceuticals Holding AG (SANN) Signs AGAMREE Deal Covering 31 Countries
– Santhera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the Caribbean
– Santhera Pharmaceuticals (SANN) Partner Files AGAMREE MAA in South Korea
Markets don't sleep, here's what's going on with S3F0 at the moment:
– Santhera Pharmaceuticals Holding AG (SANN) Signs AGAMREE Deal Covering 31 Countries
– Santhera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the Caribbean
– Santhera Pharmaceuticals (SANN) Partner Files AGAMREE MAA in South Korea
See more updates in real-time with our News Flow.
– Santhera Pharmaceuticals Holding AG (SANN) Signs AGAMREE Deal Covering 31 Countries
– Santhera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the Caribbean
– Santhera Pharmaceuticals (SANN) Partner Files AGAMREE MAA in South Korea
See more updates in real-time with our News Flow.
Santhera Pharmaceuticals Holding AG is scheduled to release its next earnings report on Apr 29, 2027.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
S3F0 stock is 1.39% volatile and has beta coefficient of 0.81.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like S3F0 are typically less volatile than smaller companies
Track every detail on Santhera Pharmaceuticals Holding AG stock chart and check out the list of the most volatile stocks — is Santhera Pharmaceuticals Holding AG there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like S3F0 are typically less volatile than smaller companies
Track every detail on Santhera Pharmaceuticals Holding AG stock chart and check out the list of the most volatile stocks — is Santhera Pharmaceuticals Holding AG there?
To understand the S3F0 stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −1.37%
– 1 week — −3.25%
– 1 month — +5.23%
S3F0 all-time low was 7.285 CHF (Oct 11, 2023), and its highest price is 17.893 CHF (May 13, 2026). Find more dynamics in the Stock Heatmap and on the Santhera Pharmaceuticals Holding AG stock chart.
– 1 day — −1.37%
– 1 week — −3.25%
– 1 month — +5.23%
S3F0 all-time low was 7.285 CHF (Oct 11, 2023), and its highest price is 17.893 CHF (May 13, 2026). Find more dynamics in the Stock Heatmap and on the Santhera Pharmaceuticals Holding AG stock chart.
Santhera Pharmaceuticals Holding AG market capitalization is 231.06 M, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Santhera Pharmaceuticals Holding AG stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Santhera Pharmaceuticals Holding AG stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Santhera Pharmaceuticals Holding AG stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Santhera Pharmaceuticals Holding AG stacks up against other companies
The safest way to buy Santhera Pharmaceuticals Holding AG stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade S3F0 directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade S3F0 directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 13, 2026, the company has 93 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Santhera Pharmaceuticals Holding AG depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Santhera Pharmaceuticals Holding AG financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our S3F0 technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — neutral
– 1-month — neutral
Combine fundamental and technical analysis for better results.
First, study Santhera Pharmaceuticals Holding AG financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our S3F0 technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — neutral
– 1-month — neutral
Combine fundamental and technical analysis for better results.
Santhera Pharmaceuticals Holding AG stock ticker depends on the exchange where it’s listed. On the SIX, its primary exchange, Santhera Pharmaceuticals Holding AG stocks trade under the symbol SANN.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
Santhera Pharmaceuticals Holding AG revenue for the last half-year amounts to 48.33 M CHF despite the estimated figure of 47.00 M CHF. In the next half-year revenue is expected to reach 36.90 M CHF.
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous periods and year-over-year data
– Track trends: One half-year matters less than consistent performance
Follow other essential metrics in Santhera Pharmaceuticals Holding AG financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous periods and year-over-year data
– Track trends: One half-year matters less than consistent performance
Follow other essential metrics in Santhera Pharmaceuticals Holding AG financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Santhera Pharmaceuticals Holding AG financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
S3F0 net income for the last half-year is −21.53 M CHF, while the half-year before that showed −10.40 M CHF of net income which accounts for −106.90% change.
How to read this data:
– Track changes: Compare net income across periods to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one period: Consistency matters more than a single result
Follow other essential metrics in Santhera Pharmaceuticals Holding AG financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across periods to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one period: Consistency matters more than a single result
Follow other essential metrics in Santhera Pharmaceuticals Holding AG financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Santhera Pharmaceuticals Holding AG does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
S3F0 reached its all-time high of 17.893 CHF on May 13, 2026. Its all-time low was 7.285 CHF and was reached on Oct 11, 2023.
Explore the Santhera Pharmaceuticals Holding AG stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Santhera Pharmaceuticals Holding AG stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Santhera Pharmaceuticals Holding AG EBITDA is −3.36 M CHF, with an EBITDA margin of −41.62%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Santhera Pharmaceuticals Holding AG statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Santhera Pharmaceuticals Holding AG statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 25.00 CHF and 25.00 CHF for S3F0, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance